Company intelligence
Allucent
Helping bring new therapies to light
About Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.
Verified activity
Signals from Allucent
8 published signals
People
Allucent welcomed Hans van Dijk as a CRO Partner for the A-Team.
Reported by Allucent
Presence & Recognition
Allucent is hosting a meeting with the Allucent team at OCT SoCal in La Jolla to discuss therapeutic and operational guidance for drug development programs.
Reported by Allucent
Presence & Recognition
Allucent is attending the RAPS Convergence USA event in Charlotte, NC, featuring booth #1006 with regulatory and drug development consulting experts including Sheila Plant, PhD, MHS, RAC, and Bianca Quade, PhD, Regulatory Affairs Scientist II.
Reported by Allucent
Research & Knowledge
Allucent published a blog exploring how AI, decentralized clinical trials, adaptive designs, modeling & simulation, and real-world evidence are reshaping the modern clinical development plan.
Reported by Allucent
People
Allucent appointed Anusha Foy as Vice President Regulatory Affairs
Reported by Anusha Foy
Presence & Recognition
Allucent is hosting a webinar with Nextrove pharmacovigilance experts on AI-enabled pharmacovigilance and practical approaches to AI in adverse event reporting and case processing.
Reported by Allucent
Presence & Recognition
Allucent is hosting a workshop session on RareTrialsSummit in Boston on Tuesday, September 15th, starting at 10:45am, led by Maria Cruz Morillo, MS, Head of Advanced Therapeutics Strategy, Rare Disease and CGT.
Reported by Allucent
Research & Knowledge
Allucent Clinical Pharmacology experts Rachel Rozakis, PharmD, and Connor Slattery published a blog examining in vitro drug-drug interaction assessments, ICH M12, and clinical DDI risk characterization.
Reported by Allucent